|
|
DRESDEN, Germany, May. 31, 2023 — denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, unveiled the broadening of its product portfolio with the launch of its first stem cell product at the annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Paris, France.
denovoMATRIX is working to accelerate the development and commercialization in the industries of cultivated meat and cell therapies with the launch of stem cell products. denovoMATRIX will supply high potency stem cells, starting with adult human bone marrow-derived mesenchymal stromal cells (MSC) at research-grade. denovoCELLS hMSC is a premium cell line product isolated and established using the biomaterial platform from denovoMATRIX in a completely serum-free process. Using this unique isolation process, denovoMATRIX can offer the MSCs at a lower population doubling level than comparable products on the market – while priced at a competitive value for customers.
denovoCELLS hMSC show advanced expansion and differentiation potential, and meets the ISCT requirements for MSC identity. By offering young and fast-growing stem cells, denovoMATRIX wants to empower scientists in the fields of basic and translational research as well as product development.
“The availability of high potency stem cells at affordable prices is aimed at enabling researchers. Our efficient isolation technology allows us to translate these benefits to our customers.’’ says Dr. Dejan Husman, CEO.
About denovoMATRIX GmbH
denovoMATRIX serves customers in cell therapy, cultivated meat and pharmaceutical research with tools for supporting cell isolation, manufacturing, and differentiation. Our offering is focused in three areas, including tailored biomaterials based on our proprietary platform, stem cell biology & characterization services, and finally high potency cell lines.
For more information, visit: https://www.denovomatrix.com/
Tell Us What You Think!